ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment

Francina Fonseca, Mònica Gratacòs, Geòrgia Escaramís, Rafael De Cid, Rocío Martín-Santos, Magi Farré, Xavier P. Estivill, Marta Torrens

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Methadone maintenance treatment is the most widely-used therapy in opioid dependence, but some patients relapse or drop out from treatment. We genotyped a genetic variant in the succinic semialdehyde dehydrogenase enzyme gene, ALDH5A1, and found that subjects carrying the T variant allele have a higher risk to be nonresponders to methadone treatment (OR=3.16; 95% CI [1.48-6.73], P=0.0024). This could be due to a reduction in the ALDH5A1 enzyme activity, that would increase endogenous gamma-hydroxbutyric acid (GHB) and gamma-aminobutyric acid (GABA) levels and therefore, inducing symptoms such as sedation and impaired pschomotor performance. These neuropsychological effects related with the reduction in enzyme activity could be responsible for a higher propensity to relapse in these genetically predisposed patients.

Original languageEnglish
Pages (from-to)420-424
Number of pages5
JournalEuropean Neuropsychopharmacology
Volume24
Issue number3
DOIs
Publication statusPublished - Mar 2014
Externally publishedYes

Fingerprint

Methadone
Opioid Analgesics
Succinate-Semialdehyde Dehydrogenase
Enzymes
Recurrence
Therapeutics
gamma-Aminobutyric Acid
Alleles
Acids
Genes

Keywords

  • ALDH5A1 gene
  • Gamma-aminobutyric acid
  • Gamma-hydroxibutyric acid (GHB)
  • Methadone maintenance treatment (MMT)
  • Opioid dependence
  • Pharmacogenetics

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Medicine(all)

Cite this

Fonseca, F., Gratacòs, M., Escaramís, G., De Cid, R., Martín-Santos, R., Farré, M., ... Torrens, M. (2014). ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment. European Neuropsychopharmacology, 24(3), 420-424. https://doi.org/10.1016/j.euroneuro.2013.10.003

ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment. / Fonseca, Francina; Gratacòs, Mònica; Escaramís, Geòrgia; De Cid, Rafael; Martín-Santos, Rocío; Farré, Magi; Estivill, Xavier P.; Torrens, Marta.

In: European Neuropsychopharmacology, Vol. 24, No. 3, 03.2014, p. 420-424.

Research output: Contribution to journalArticle

Fonseca, F, Gratacòs, M, Escaramís, G, De Cid, R, Martín-Santos, R, Farré, M, Estivill, XP & Torrens, M 2014, 'ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment', European Neuropsychopharmacology, vol. 24, no. 3, pp. 420-424. https://doi.org/10.1016/j.euroneuro.2013.10.003
Fonseca, Francina ; Gratacòs, Mònica ; Escaramís, Geòrgia ; De Cid, Rafael ; Martín-Santos, Rocío ; Farré, Magi ; Estivill, Xavier P. ; Torrens, Marta. / ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment. In: European Neuropsychopharmacology. 2014 ; Vol. 24, No. 3. pp. 420-424.
@article{6679c36823d34f05a3817ce6d3b363df,
title = "ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment",
abstract = "Methadone maintenance treatment is the most widely-used therapy in opioid dependence, but some patients relapse or drop out from treatment. We genotyped a genetic variant in the succinic semialdehyde dehydrogenase enzyme gene, ALDH5A1, and found that subjects carrying the T variant allele have a higher risk to be nonresponders to methadone treatment (OR=3.16; 95{\%} CI [1.48-6.73], P=0.0024). This could be due to a reduction in the ALDH5A1 enzyme activity, that would increase endogenous gamma-hydroxbutyric acid (GHB) and gamma-aminobutyric acid (GABA) levels and therefore, inducing symptoms such as sedation and impaired pschomotor performance. These neuropsychological effects related with the reduction in enzyme activity could be responsible for a higher propensity to relapse in these genetically predisposed patients.",
keywords = "ALDH5A1 gene, Gamma-aminobutyric acid, Gamma-hydroxibutyric acid (GHB), Methadone maintenance treatment (MMT), Opioid dependence, Pharmacogenetics",
author = "Francina Fonseca and M{\`o}nica Gratac{\`o}s and Ge{\`o}rgia Escaram{\'i}s and {De Cid}, Rafael and Roc{\'i}o Mart{\'i}n-Santos and Magi Farr{\'e} and Estivill, {Xavier P.} and Marta Torrens",
year = "2014",
month = "3",
doi = "10.1016/j.euroneuro.2013.10.003",
language = "English",
volume = "24",
pages = "420--424",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment

AU - Fonseca, Francina

AU - Gratacòs, Mònica

AU - Escaramís, Geòrgia

AU - De Cid, Rafael

AU - Martín-Santos, Rocío

AU - Farré, Magi

AU - Estivill, Xavier P.

AU - Torrens, Marta

PY - 2014/3

Y1 - 2014/3

N2 - Methadone maintenance treatment is the most widely-used therapy in opioid dependence, but some patients relapse or drop out from treatment. We genotyped a genetic variant in the succinic semialdehyde dehydrogenase enzyme gene, ALDH5A1, and found that subjects carrying the T variant allele have a higher risk to be nonresponders to methadone treatment (OR=3.16; 95% CI [1.48-6.73], P=0.0024). This could be due to a reduction in the ALDH5A1 enzyme activity, that would increase endogenous gamma-hydroxbutyric acid (GHB) and gamma-aminobutyric acid (GABA) levels and therefore, inducing symptoms such as sedation and impaired pschomotor performance. These neuropsychological effects related with the reduction in enzyme activity could be responsible for a higher propensity to relapse in these genetically predisposed patients.

AB - Methadone maintenance treatment is the most widely-used therapy in opioid dependence, but some patients relapse or drop out from treatment. We genotyped a genetic variant in the succinic semialdehyde dehydrogenase enzyme gene, ALDH5A1, and found that subjects carrying the T variant allele have a higher risk to be nonresponders to methadone treatment (OR=3.16; 95% CI [1.48-6.73], P=0.0024). This could be due to a reduction in the ALDH5A1 enzyme activity, that would increase endogenous gamma-hydroxbutyric acid (GHB) and gamma-aminobutyric acid (GABA) levels and therefore, inducing symptoms such as sedation and impaired pschomotor performance. These neuropsychological effects related with the reduction in enzyme activity could be responsible for a higher propensity to relapse in these genetically predisposed patients.

KW - ALDH5A1 gene

KW - Gamma-aminobutyric acid

KW - Gamma-hydroxibutyric acid (GHB)

KW - Methadone maintenance treatment (MMT)

KW - Opioid dependence

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=84894372285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894372285&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2013.10.003

DO - 10.1016/j.euroneuro.2013.10.003

M3 - Article

VL - 24

SP - 420

EP - 424

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 3

ER -